

# Senseonics to Participate in the Canaccord Genuity Growth Conference



July 25, 2019

**8/8/19 Update: Presentation cancelled due to travel disruption.**

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA.

Management is scheduled to present Thursday, August 8, 2019 at 9:30am ET. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company's website at [www.senseonics.com](http://www.senseonics.com).

## About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense<sup>®</sup> and Eversense<sup>®</sup> XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20190725005846/en/>

## Senseonics Investor Relations Contact:

Lynn Lewis or Philip Taylor

Investor Relations

415-937-5406

[Investors@senseonics.com](mailto:Investors@senseonics.com)

Source: Senseonics Holdings, Inc.